EZEvangelia Zapanti

Evangelia Zapanti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Evangelia Zapanti has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The role of the stress adaptive response in multiple sclerosis

    by Evangelia Zapanti, Alexandros Dermentzoglou, Paraskevi Kazakou, Konstantinos Kilindireas, George Mastorakos


  • Open Access

    High-Dose Intravenous Steroid Treatment Seems to Have No Long-Term Negative Effect on Bone Mineral Density of Young and Newly Diagnosed Multiple Sclerosis Patients: A Pilot Study

    by George Simeakis, Maria Anagnostouli, Nikolaos Fakas, John Koutsikos, Athanasios Papatheodorou, Konstantinos Chanopoulos, Kwnstantinos Athanasiou, George Papatheodorou, Evangelia Zapanti, Maria Alevizaki, et al.

    High-dose intravenous steroid treatment (HDIST) represents the first choice of treatment for multiple sclerosis (MS) relapses. Chronic oral glucocorticoid (GC) administration correlates with bone loss whereas data regarding HDIST in MS are still conflicting. Twenty-five newly diagnosed MS patients (NDMSP) (median age: 37 years) were prospectively studied for the effects of HDIST on bone mineral density (BMD) and bone metabolism. Patients received 1000 mg methylprednisolone intravenously every day for 5 days followed by oral prednisolone tapering over 21 days. Bone metabolism indices were determined prior to GC, on days 2, 4, 6, and 90, and at months 6, 12, 18, and 24 post GC therapy. Femoral, lumbar-spine BMD, and whole-body measurement of adipose/lean tissue were assessed prior to GC-administration and then every six months. Ten patients completed the study. N-terminal-propeptide-procollagen-type-1 and bone-specific alkaline phosphatase showed a significant increase at day-90 (p < 0.05). A transient non-significant fall of BMD was observed at 6 months after GC-administration, which subsequently appeared to be restored. We conclude that HDIST seems not to have long-term negative effects on BMD, while the observed transient increase of bone formation markers probably indicates a high bone turnover phase to GC-administration. Additional prospective studies with larger sample size are needed.


  • Dysfunction of the Hypothalamic-Pituitary-Adrenal axis in HIV infection and disease

    by Evangelia Zapanti, Konstantinos Terzidis, George Chrousos

    Abnormalities of the hypothalamic-pituitary-adrenal (HPA) axis have been documented in HIV patients in the early as well as late stages of the infection and range from subtle subclinical disturbances to frank adrenal insufficiency. Potential etiologies of these disorders include opportunistic infections, neoplasms, drugs administered to treat infections, cytokine abnormalities associated with the HIV disease process and acquired alterations in tissue sensitivity to glucocorticoids. In this article, we present a concise review of HPA abnormalities in HIV infection and disease with regard to their etiology with emphasis on syndromes of hypersensitivity/resistance to glucocorticoids associated with antiviral medications and/or the HIV infection itself.


  • Pheochromocytoma: Physiopathologic Implications and Diagnostic Evaluation

    by Evangelia Zapanti, Ioannis Ilias

    Pheochromocytoma (PHEO) is a chromaffin cell tumor embryologically arising from the neural crest tissue. The dominant secretory products of PHEO are catecholamines: noradrenaline (norepinephrine), adrenaline (epinephrine), and to a lesser extent dopamine. In addition to catecholamines, PHEO cells also elaborate and release several neuropeptides and inflammatory cytokines which can exert intra-adrenal and extra-adrenal systemic effects and cause characteristic clinical syndromes. In a concise review we present the intra-adrenal and extra-adrenal pathophysiologic implications of PHEO and the nuclear medicine modalities that permit functional imaging of physiological processes and help localize these tumors. The specific pathways of synthesis, metabolism, and inactivation of catecholamines (of PHEOs and paragangliomas) can be used as means to develop suitable tracers for positron emission tomography (PET) ligands. In this review we focus on imaging with PET using [(18)F]-fluorodopamine, [(18)F]-fluorohydroxyphenylalanine, [(11)C]-epinephrine, or [(11)C]-hydroxyephedrine and examine how functional imaging can often complement traditional anatomical imaging modalities and other scintigraphic techniques.


    • 1 January 2006
      • p. 208-13

    Treatment options of polycystic ovary syndrome in adolescence.

    by Evangelia Zapanti, Erasmia Kiapekou, Dimitrios Loutradis

    The polycystic ovary syndrome (PCOS) is defined as a syndrome of hyperandrogenism and chronic anovulation in the absence of other underlying pituitary or adrenal disorders. PCOS often presents in adolescence and is the commonest cause of menstrual disorders and hirsutism. Premature adrenarche and hirsutism that occur before puberty have been associated with PCOS. The etiology of the syndrome is as yet uncertain. Theories have focused on intrinsic defects in the ovarian and adrenal steroidogenesis, and on the role of insulin resistance in modifying reproductive function. Insulin resistance associated with PCOS confers a markedly increased risk of impaired glucose tolerance and type 2 diabetes mellitus in adolescent girls, as in premenopausal women. Therapeutic considerations focus on the management of menstrual irregularities and hyperandrogenism, as well as on the prevention of the metabolic consequences of the syndrome.